Nonhypoglycemic effects of thiazolidinediones

Medicine and Dentistry

• Thiazolidinedione 100%
• Drug 66%
• Chemotherapeutic Agent 66%
• Rosiglitazone 33%
• Maturity Onset Diabetes of the Young 33%
• Pioglitazone 33%
• Troglitazone 33%
• Receptor 16%
• Cardiovascular System 16%
• Glucose 16%
• In Vitro 16%
• Patient with Type 2 Diabetes 16%
• Low-Density Lipoprotein 16%
• Blood Pressure 16%
• Diabetes Mellitus 16%
• Cardiovascular Disease 16%
• Cardiovascular Risk 16%
• Adverse Event 16%
• Insulin Resistance 16%
• Liver Injury 16%
• Low Density Lipoprotein Cholesterol 16%
• Coronary Artery Disease 16%
• Metabolic Syndrome 16%
• Carotid Artery 16%
• Dyslipidemia 16%
• Peroxisome Proliferator Activated Receptor 16%
• Intima-Media Thickness 16%
• Fibrinolysis 16%
• Insulin Sensitizing Agent 16%
• Liver Failure 16%
• Artery Intima 16%
• Therapeutic Procedure 16%
• Aptitude 16%
• Mechanism of Action 16%
• Inpatient 16%
• Plasma 16%
• Atherosclerosis 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug 66%
• Non Insulin Dependent Diabetes Mellitus 33%
• Rosiglitazone 33%
• Pioglitazone 33%
• Troglitazone 33%
• Clinical Trial 33%
• Receptor 16%
• Adverse Event 16%
• Insulin 16%
• Insulin Resistance 16%
• Atherosclerosis 16%
• Low Density Lipoprotein 16%
• Liver Injury 16%
• Diabetes Mellitus 16%
• Metabolic Syndrome X 16%
• Glucose 16%
• Cardiovascular Risk 16%
• Dyslipidemia 16%
• Insulin Sensitizing Agent 16%
• Low Density Lipoprotein Cholesterol 16%
• Peroxisome Proliferator Activated Receptor 16%
• Liver Failure 16%
• Coronary Artery Disease 16%